Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

Inclusion criteria: \- Participants receiving a lipid-lowering treatment other than atorvastatin/ or not at stable dose of atorvastatin 10 mg for at least 6 weeks prior to screening, or drug naive participants with primary hypercholesterolemia if they are likely to have low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL (≥ 2.59 mmol/L) at the end of the 6-week run-in treatment period on atorvastatin therapy OR \- Participants with primary hypercholesterolemia treated with stable dose of atorvastatin 10 mg for at least 6 weeks prior to screening and likely to have low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL (≥ 2.59 mmol/L) at the screening visit. Exclusion criteria: 1. LDL-C \< 100 mg/dL (\< 2.59 mmol/L) at Week -1 (V1): * After the run-in period on atorvastatin 10 mg for participants receiving a lipid lowering treatment other than atorvastatin/ or not at stable dose of atorvastatin 10 mg for at least 6 weeks prior to the screening period, or drug naive participants. OR * At the first visit for participants who are being treated with atorvastatin 10 mg at stable dose for at least 6 weeks prior to screening visit. 2. Participants not previously instructed on a cholesterol-lowering diet. 3. Participants with type 1 diabetes. 4. Participants with type 2 diabetes treated with insulin. 5. Participants with type 2 diabetes and with an HbA1c ≥ 8.5% at screening visit (considered poorly controlled). 6. Laboratory findings measured before randomization: * Triglycerides (TG) \> 350 mg/dL (\> 3.95 mmol/L) at screening visit. * Positive serum or urine pregnancy test in females of childbearing potential. 7. Pregnant or breast-feeding women. 8. Women of childbearing potential with no effective contraceptive method. The above information is not intended to contain all considerations relevant to a Participant's potential participation in a clinical trial.